PROMOTE ADOPTION OF IN SILICO TRIALS THROUGH EMA’S STRATEGY ON REGULATORY SCIENCE TO 2025

Sign our on line petition. Together we can make the difference!

The EMA (European Medicines Agency) recognizes the importance of emerging technologies like modelling and simulation (also known as in silico methods),

but their strategy stresses almost exclusively on the reduction of animal experimentation.

This is a relevant application, but it is not the only one nor the most impactful for patients and industries.

In Silico Trials is not only related to pre-clinical evaluation, but also to the reduction, refinement, and in some cases even replacement of clinical trials.

Read more on change.org